PTPRC and cancer: By examining the population proportion breakdown in the TME by immune phenotype metadata (Fig. 1e, Supplemental Fig. 1), we found that semi-supervised labeling of the 16 tumors matches the originally published findings with respect to immune phenotype, where in infiltrated tumors there are most CD45+ cells relative to cancer cells, fewer CD45+ cells relative to cancer cells in excluded tumors, and fewest CD45+ cells relative to cancer cells in desert tumors.